glp-1/gip dual agonist lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Five Unexpected New Uses for

Nangaku M, Wanner C

The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension: Body Weight

Treatment-regimen estimand refers to the efficacy of treatment of persistent severe hyperglycemia regardless of whether the study drug is adhered to or whether rescue therapy is used

It represents a strategic evolution in therapeutic development, moving beyond single-target approaches to multi-receptor agonism

D.IshikawaM.LeeB

However, these studies did not specifically include patients with kidney disease, and the numbers of hard kidney outcomes reached (i.e., kidney transplantation, initiation of maintenance dialysis, death from kidney failure, or a sustained low GFR) were too low to make definitive conclusions on the renoprotective effects of GLP-1 receptor agonists